生物制药公司Akero Therapeutics今日盘中大涨7.89%,引起市场广泛关注。
消息面上,近期多家分析师机构相继上调了对Akero的目标股价预期。Canaccord Genuity将其目标价从56美元上调至73美元,H.C. Wainwright也从50美元上调至72美元。此外,摩根大通更是将目标价从49美元大幅上调至73美元,对该公司发展前景给予高度评价。
分析师为何如此看好Akero?Akero主攻非酒精性脂肪性肝病的治疗领域,该领域存在着巨大的未满足医疗需求。公司核心产品近期取得了阶段性临床试验数据,数据令人鼓舞,彰显了产品的疗效和安全性,因此市场对Akero的长期成长潜力更加看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.